Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
HDV-Insulin Lispro (HDV-LIS) met A1C non-inferiority at Weeks 12 and 25, confirming comparable glycemic control to insulin ...
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from three Phase 3 ...
Full results from two Lilly trials of the novel triple hormone receptor agonist show reductions in A1c, osteoarthritis knee pain, and obstructive sleep apnea.
DexCom Inc. DXCM stock is trading higher on Monday after the diabetes management company reported positive results from its ...
AstraZeneca’s experimental GLP-1 pill cut body weight by nearly 12% in obese patients over 36 weeks and reduced A1C, a metric ...
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced ...
Discordance between continuous glucose monitoring measures and A1c should not always be interpreted as measurement errors, ...
CONSTANTLYGUZZLING WATER but still feeling thirsty, always having to pee, and experiencing never-ending fatigue can all be signs of type 2 diabetes. You might also have tingling or numbness in your ...
Dear Doctors: My blood tests show that I am prediabetic. I am puzzled because I am not overweight, I get plenty of exercise and I eat quite a bit of fiber every day. I don’t eat many sweets, but I do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results